Open AccessIn Vivo Antiarrhythmic Profile of AP-792 Assessed in Different Canine Arrhythmia Models
Author(s) -
Akira Takahara,
Akira Hirasawa,
Hideki Dohmoto,
Masataka Shoji,
Ryota Yoshimoto,
Atsushi Sugiyama,
Keitaro Hashimoto
Publication year - 2001
Publication title -
japanese journal of pharmacology/japanese journal of pharmacology
Language(s) - English
Resource type - Journals
eISSN - 1347-3506
pISSN - 0021-5198
DOI - 10.1254/jjp.87.21
Subject(s) - medicine , pharmacology , cardiology , digitalis , dofetilide , anti arrhythmia agents , qt interval , heart failure , atrial fibrillation
The antiarrhythmic effects of a novel antiarrhythmic drug AP-792, 4-(5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-[4-cyclohexylbutyl]piperidine hydrochloride, were analyzed using the epinephrine-, digitalis- and two-stage coronary ligation-induced canine ventricular arrhythmia models. Intravenous administration of AP-792 (0.3 or 1.0 mg/kg) effectively suppressed each of the ventricular arrhythmias, an action that resembles that of a typical cardioselective Ca2+ channel blocker, AH-1058. The antiarrhythmic action of AP-792 was slow in onset and longer-lasting than those in our previous studies using more than 50 antiarrhythmic drugs, including Na+ and Ca2+ channel blockers. These results suggest that AP-792 can become a unique long-acting antiarrhythmic drug.